Mechanisms of Chemotherapy Resistance in T-ALL

The goals of this study are to unravel the molecular mechanisms underlying leukemic transformation and chemotherapy resistance in T-cell acute lymphoblastic leukemia (T-ALL). Towards this end, a cohort of T-ALL lymphoblast specimens was collected at the time of initial T-ALL diagnosis (prior to the start of therapy) from children enrolled on contemporary clinical trials, Children's Oncology Group study AALL0434 and Dana-Farber Cancer Institute 05-001. Samples were analyzed using targeted exon sequencing and RNA sequencing analysis. Results of these analyses form the basis of studies that have been submitted for publication, and will be linked to this entry once published.]]>
This study included childhood T-cell acute lymphoblastic leukemia (T-ALL) specimens collected at the time of initial diagnosis, prior to initiation of therapy, from patients enrolled on clinical trials Dana-Farber Cancer Institute Study 05-001 (https://clinicaltrials.gov/ct2/show/NCT00400946), and Children's Oncology Group Study AALL0434 (https://clinicaltrials.gov/ct2/show/NCT00408005). Criteria for data inclusion included availability of adequate tumor material for analysis, and appropriate informed consent and institutional review board (IRB) approval of the respective institutions, in accordance with the Declaration of Helsinki.]]>
The goal of this study is to improve our understanding of the molecular genetics of T-cell acute lymphoblastic leukemia, including the molecular factors that govern treatment response and resistance. Genomic DNA was analyzed by targeted exon sequencing for protein-coding exons of the genes listed below. RNA sequencing analysis was also performed on a subset of samples. ]]>